Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

NCT03972345 | Enrolling By Invitation

• 2 other identifiers: GH-4488U1111-1217-5835
• Study Type: observational
• Target: 750
• Locations: 1 country
• Sites: 1

Brief Summary

Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and teenagers in daily practice in Germany. This study will look mainly at the difference in near final height between children and teenagers who adhere to their therapy plan with Norditropin® to non-adherent patients. Participants will get Norditropin® as prescribed to them by their doctor. The study will last as long as the therapy with growth hormone is seen necessary by the participants' doctors and the participants, up to a maximum of 10 years. During the visits at the participants' doctors participants will be asked to fill in a questionnaire.

Conditions

Growth Hormone Deficiency in Children; Born Small for Gestational Age

Outcome Measures

Primary Outcomes (1)

• Near final height (NFH) standard deviation score (SDS) measured in scores

  SDS, -3 to +3

  At the end of the study (up to 10 years)

Secondary Outcomes (5)

• Change in growth rate (height velocity standard deviation score, HV SDS)

  From baseline (month 0) to end of study (up to 10 years)

• Change in growth rate (HV SDS) between visits (usually patients are seen every 3 to 6 months)

  From baseline (month 0) to end of study (up to 10 years)

• Adherence response as indicated in question at the bottom of newly developed Patient Reported Outcome (PRO) questionnaire each time questionnaire is filled out (preferably at each visit)

  From baseline (month 0) to end of study (up to 10 years)

• Adherence measured as number of medication devices returned versus number of prescribed devices for the period between visits

  From baseline (month 0) to end of study (up to 10 years)

• Change of self-rated adherence level throughout the study measured in newly developed PRO questionnaire each time questionnaire is filled out (preferably at each visit)

  From baseline (month 0) to end of study (up to 10 years)

Study Arms (1)

Paediatric patients with iGHD or SGA

Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)

Drug: Norditropin® FlexPro®

Interventions

Norditropin® FlexPro® DRUG

Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.

Paediatric patients with iGHD or SGA

Eligibility Criteria

• Age: 0 Years - 15 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Paediatric patients with iGHD or SGA.

You may qualify if:

• Informed consent of parent or legally acceptable representative of subject and child assent, as age-appropriate must be obtained before any study-related activities.
• The parent or legally acceptable representative of the child must sign and date the Informed Consent Form (according to local requirements) and
• The child must sign and date the Child Assent Form or provide oral assent (if required according to local requirements).
• The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
• Male or female, all age groups equal to or below 15 years with more than 2 years expected remaining treatment time until reaching NFH. Patients who self-inject should be above 8 years of age in order to be able to fill in the questionnaire.
• Children being GH naïve at baseline with one of the following confirmed diagnoses
• Isolated growth hormone deficiency (iGHD)
• Small for gestational age (SGA)

You may not qualify if:

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
• Patients who have an expected future duration of therapy of less than 2 years are not eligible for the study.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ)

Ulm, 89075, Germany

Location

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2019
• First Posted: June 3, 2019
• Study Start: June 21, 2019
• Primary Completion (Estimated): June 30, 2029
• Study Completion (Estimated): June 30, 2031
• Last Updated: September 25, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)